Filter News

Genelabs Technologies, Inc. To Present At The Rodman & Renshaw Techvest 7th Annual Healthcare Conference

Published: Nov 03, 2005

REDWOOD CITY, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that it will present a company update at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the Palace Hotel in New York on Monday, November 7, 2005 at 11:35 a.m. local time.

(Logo: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at www.genelabs.com or through the following URL: http://www.wsw.com/webcast/rrshq7/gnlb/ . The presentation will also be available for replay after the presentation for a limited time.

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also exploring options for development of a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on attending and presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference and regarding the progress of the Company's lupus and hepatitis C virus programs. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, failures or delays in the lupus or hepatitis C programs, unexpected expenses and Genelabs' capital requirements and history of operating losses. Please see the information appearing in the Genelabs' filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, under the captions "Risk Factors" and "Forward- Looking Statements" for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company or cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release.

Contact: Matthew M. Loar

Chief Financial Officer

Phone: 650-562-1424

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comGenelabs Technologies, Inc.

CONTACT: Matthew M. Loar, Chief Financial Officer of GenelabsTechnologies, Inc., +1-650-562-1424

Back to news